natgillin/translations-raw huggingface dataset:
Objektivt respons: Objektivt respons var defineret som den andel af forsøgspersoner med registrerbare sygdomme, der opnåede et fuldstændigt eller delvist respons ifølge RECIST-kriterier (baseline- lymfeknudestørrelse skulle være over ≥ 2 cm for at blive anset for en target-læsion).
Objective response: Objective response was defined as the proportion of subjects with measurable disease achieving a complete or partial response according to RECIST criteria (baseline lymph node size was required to be ≥ 2 cm to be considered a target lesion).
Objektivt tumorrespons / varighed af respons/progression
Objective tumour responses / duration of response / progression
OBS!
Remember
OBS: HOLD IKKE DEN GRØNNE KNAP NEDE, MENS DU TRÆKKER VEJRET IND.
ATTENTION: DO NOT HOLD THE GREEN BUTTON DOWN WHILE YOU ARE INHALING.
Observation N=1.693
Observation N=1693
Observation N=1.697***
Observation N= 1697
Observationelle studier af varicella-vaccinens langvarige virkning
Observational studies of long-term effectiveness of varicella vaccine
Observationen kan være en tilfældighed eller relateret til en mekanisme, som på nuværende tidspunkt ikke er kendt (se pkt.
The event may be a chance finding or related to a mechanism currently not known (see also section 5.1).
Observationen kan være en tilfældighed eller relateret til en mekanisme, som på nuværende tidspunkt ikke er kendt (se pkt.
The event may be a chance finding or related to a mechanism currently not known (see section 5.1).
Observationer efter markedsføring
Post-marketing observations
observations-registreringsstudie skal vurdere resultatet af graviditet hos kvinder der
observational registry study shall evaluate the outcomes of pregnancy in women
Observationsstudie til overvågning af sikkerhed efter markedsføring
Post-marketing observational safety surveillance study
Observatørblindet beskrivelse af fotos (blindet beskrivelse), gennemsnit af ekspertbeskrivelse
Observer-blinded photo assessment (blinded read), mean expert evaluation
Observer patienten i 30 minutter med henblik på allergisk reaktion eller hypersensitivitetsreaktion (af straks-typen).
Observe the patient for 30 minutes to ensure that you will notice if the patient develops an allergic or hypersensitivity reaction (immediate type).
observerede farmakokinetiske
observed pharmacokinetic
Observerede forandringer i laboratorieværdier er stigning i leukocytter, basofile, eosinofile, monocytter og neutrofile, ASAT, ALAT, LDH, total bilirubin og total protein; fald i erythrocytter og total protein.
Observed changes in the laboratory parameters are: increased WBC count, basophils, eosinophils, monocytes and neutrophils, AST, ALT, LDH, total bilirubin and total protein; lowered RBC count and total protein.
Observerede fordele med hensyn til lungefunktion og P. aeruginosa-suppression skal vurderes i sammenhæng med patientens tolerance af TOBI Podhaler.
Observed benefits on lung function and P. aeruginosa suppression should be assessed in the context of the patient’s tolerance of TOBI Podhaler.
Observerede stigninger i ALAT og/eller ASAT
Observed elevations of ALT and/or AST
Observeret analyse
Observed analysis
Observeret difference (95 % CI) ±
Observed difference (95% CI) ±
Observeret hos mindst 2 forsøgspersoner med samme undertype.
Observed in at least 2 subjects of the same subtype.
Observeret hos patienter med Parkinsons sygdom
Observed in patients with Parkinson’s disease
Observeret i kombination hos 6 % (4/67) af forsøgspersonerne.
Observed in combination in 6% (4/67) of the subjects.
Observeret i kombination hos genotype 1b-smittede forsøgspersoner.
Observed in combination in genotype 1b-infected subjects.
Observeret med paliperidon efter markedsføringen.
Observed post-marketing with paliperidone
obsessiv adfærd
obsessive behaviour(s)
Obsessiv-
Obsessive
Obsessiv- kompulsiv tilstand, agitationd
Obsessive- compulsive disorder, agitationd
obstipati on
constipation
Obstipation
Abdominal pain
Obstipation
Very Common
Obstipation (22,3 %) (G3/4: 0,7 %)d
Constipation (22.3%) (G3/4: 0.7%)d
Obstipation (43%) Abdominalsmerterj (21%)
Constipation (43%) Abdominal painj (21%)
Obstipation (G3/4: 0,4%)
Constipation (G3/4: 0.4%)
Obstipation (G3/4: 1,0%); Gastrointestinale smerter (G3/4: 1,0%);
Constipation (G3/4: 1.0%); Gastrointestinal pain (G3/4: 1.0%);
Obstipation Abdominal- smerter
Constipation Abdominal pain
Obstipation Diarré
Constipation
Obstipation Diarré Abdominal- smerter Opkastning Dyspepsi Flatulens
Constipation Diarrhoea Abdominal pain Vomiting Dyspepsia Flatulence
Obstipation Diaré
Constipation Diarrhoea
Obstipation eller oppustethed kan forekomme.
Constipation or bloating could occur.
Obstipation er en klasseeffekt af vinca-alkaloider: 12% af patienterne oplevede svær obstipation under behandlingen med vinflunin.
Constipation is a class effect of the vinca alkaloids: 11.8% of patients experienced severe constipation during treatment with vinflunine.
Obstipation Kvalme Abdominalsmerter2 Opkastning Flatulens
Constipation Nausea Abdominal pain2 Vomiting Flatulence
Obstipation Mundtørhed
Constipation Dry mouth
Obstipation Opkastning Pankreatitis2
Constipation Vomiting Pancreatitis2
Obstipation ≥ grad 3 forekom hos 15,3% af de behandlede patienter.
Grade ≥ 3 constipation occurred in 15.3% of treated patients.
Obstipation, anoreksi, diarré, mukosit
Constipation, anorexia, diarrhoea, mucositis
Obstipation, der ikke er forbundet med brug af opioider
Constipation not related to opioid use
Obstipation, Dyspepsi
Constipation, Dyspepsia
Obstipation, dyspepsi
Hypersensitivity
Obstipation, dyspepsi, gastritis, abdominalsmerter, mundtørhed, abdominalgener, oppustethed, gingivitis, melæna, tandpine
Constipation, dyspepsia, gastritis, abdominal pain, dry mouth, abdominal discomfort, abdominal distension, gingivitis, melaena, toothache
Obstipation, gastroøsofageal refluks, gingivalblødning, dysfagi
Constipation, gastro- oesophageal reflux disease, gingival bleeding, dysphagia
Obstipation, kvalme, opkastning
Constipation, nausea, vomiting
Obstipation, mundtørhed, pankreatitisC
Constipation, dry mouth, pancreatitisC
Obstipation, nekrotiserende stomatitis, dysfagi
Constipation, stomatitis necrotising, dysphagia
obstipation, opstød, gastrit, stomatit, opkastning, forværring af gastrointestinal inflammation
Constipation, eructation, gastritis, stomatitis, vomiting, aggravation of gastrointestinal inflammation
Obstipation, stomatitis, mundtørhed
Constipation, stomatitis, dry mouth
Obstipation, tør hud, asteni, muskelspasmer, diarré, artralgi, abdominalsmerter, opkastning og perifert ødem blev observeret mindre hyppigt (<10 % og ≥5 %), var lette til moderate, håndterbare og krævede ikke dosisreduktion.
Constipation, dry skin, asthenia, muscle spasms, diarrhoea, arthralgia, abdominal pain, vomiting and peripheral oedema were observed less commonly (<10% and ≥5%) were of mild to moderate severity, manageable and generally did not require dose reduction.
Obstipation; Øsofagitis/dysfagi/ Odynofagi (G3/4: 0,6%);
Constipation; Esophagitis/dysphagia/ odynophagia (G3/4: 0.6%);
Obstipation†
Constipation
Obstiperede patienter skal overvåges nøje under behandling med Sevelamer carbonate Zentiva.
Patients who are constipated should be monitored carefully while being treated with Sevelamer carbonate Zentiva.
obstruktion af blodårer i øjet, synsforstyrrelser
obstruction of the blood vessels in the eye, visual disturbance
obstruktion af blærehalsen
gall bladder obstruction
Obstruktion af venstre ventrikels udløb (f.eks. obstruktiv hypertrofisk kardiomyopati og udtalt aortastenose).
Obstruction of the outflow tract of the left ventricle (e.g. hypertrophic obstructive cardiomyopathy and high grade aortic stenosis).
Obstruktion i udløbet fra venstre ventrikel (f.eks. aortastenose i svær grad)
Obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis)
obstruktion,
Intestinal obstruction,
Obstruktiv galdegangslidelse bør udelukkes hos patienter med forhøjede ALAT- og ASAT-tal eller hos patienter, som tidligere har været i behandling med en somatostatinanalog.
Evidence of obstructive biliary tract disease should be ruled out in patients with elevations of ALT and AST or in patients with a prior history of treatment with any somatostatin analogue.
Obstruktiv luftvejssygdom
Obstructive airways disorder
Obstruktive galdelidelser
Biliary obstructive disorders
Oclacitinib udviser lav proteinbinding med 66,3% til 69,7% bundet til beriget hundeplasma ved nominelle koncentrationer i området 10 til 1.000 ng/ml.
Oclacitinib exhibits low protein binding with 66.3% to 69.7% bound in fortified canine plasma at nominal concentrations ranging from 10 to 1,000 ng/ml.
Oclacitinib-tabletter blev administreret til raske, 1-år gamle beaglehunde to gange dagligt i 6 uger, efterfulgt af én gang dagligt i 20 uger, med 0,6 mg/kg kv, 1,8 mg/kg kv og 3,0 mg/kg kv i 26 uger i alt.
Oclacitinib tablets were administered to healthy, one year old Beagle dogs twice daily for 6 weeks, followed by once per day for 20 weeks, at 0.6 mg/kg bw, 1.8 mg/kg bw and 3.0 mg/kg bw for a total of 26 weeks.
Oclacitinibmaleats absolutte biotilgængelighed var 89%.
The absolute bioavailability of oclacitinib maleate was 89%.
Oclacitinibs totale kropsclearance fra plasma var lav – 316 ml/t/kg kropsvægt (5,3 ml/min/kg kropsvægt) og det tilsyneladende distributionsvolumen ved steady-state var 942 ml/kg kropsvægt.
Total body oclacitinib clearance from plasma was low – 316 ml/h/kg bodyweight (5.3 ml/min/kg bodyweight), and the apparent volume of distribution at steady-state was 942 ml/kg bodyweight.
OCT1 ved kliniske relevante koncentrationer.
OCT1 at clinically relevant concentrations.
OCT2- og MATE1- medieret transport af tipiracilhydrochlorid kan være påvirket, når Lonsurf administreres samtidig med hæmmere af OCT2 og MATE1.
Transport of tipiracil hydrochloride by OCT2 and MATE1 might be affected when Lonsurf is administered concomitantly with inhibitors of OCT2 and MATE1.
Octapharma AB, Lars Forssells gata 23, 112 75 Stockholm, Sverige
Octapharma AB, Lars Forssells gata 23, 112 75 Stockholm, Sweden
Octapharma Benelux (Belgium)
Nederland Octapharma Benelux (Belgium)
Octapharma Limited Tel: +44 161 8373770
United Kingdom Octapharma Limited Tel: +44 161 8373770
Octocog alfa er et glycoprotein bestående af 2332 aminosyrer med en omtrentlig molekylemasse på 280 kD.
Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD.
Octreotid og lanreotid (til behandling af akromegali, en sjælden hormonel sygdom, der sædvanligvis forekommer hos midaldrende voksne og skyldes, at hypofysen danner for meget væksthormon) kan begge øge eller reducere dit blodsukker.
Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle–aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.
Octreotid og lanreotid (til behandling af akromegali, en sjælden hormonel sygdom, der sædvanligvis forekommer hos midaldrende voksne og skyldes, at hypofysen danner for meget væksthormon) kan enten øge eller reducere dit blodsukker.
Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle–aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.
Octreotid og lanreotid (til behandling af akromegali, en sjælden hormonel sygdom, der sædvanligvis forekommer hos midaldrende voksne og skyldes, at hypofysen danner for meget væksthormon) kan enten øge eller reducere dit blodsukkerniveau.
Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle–aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.
Octreotid og lanreotid (til behandling af akromegali, som er en sjælden hormonel sygdom, der sædvanligvis forekommer hos midaldrende voksne, og som skyldes at hypofysen danner for meget væksthormon) kan enten øge eller reducere dit blodsukkerniveau.
Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle-aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.
Octreotid og lanreotid – til behandling af en sjælden lidelse hvor der produceres for meget væksthormon (akromegali).
Octreotide and lanreotide – used for treatment of acromegaly (a rare illness with too much growth hormone).
Octreotid og lanreotid – til behandling af en sjælden lidelse med for meget væksthormon (akromegali).
Octreotide and lanreotide – used to treat a rare condition involving too much growth hormone (acromegaly).
octreotid,
octreotide,
Octylsalicylat Isopropylalkohol
Octyl salicylate Isopropyl alcohol
od omkring mund, næse og/eller oropharynx ændret mental status
oot present around mouth, nose and/or oropharynx altered mental status
Odds ratio (95 %
Odds ratio (95% CI)
Odds ratio (95 % CI)
Odds ratio (95% CI)
Odds ratio (95 % CI)+
Odds ratio (95% CI)+
Odds ratio (95 % konfidensinterval)
Odds ratio (95% CI)
Odds ratio 1,56;
Odds ratio 1.56;
Odds ratio 8,9 (95% CI: 2,7; 29,2)
Odds ratio 8.9; (95% CI: 2.7, 29.2)
Odds ratio1 (95 % CI)
Odds Ratio1 (95%CI)
Odds-ratio
Placebo
Oddsrate (95% CI)
Odds Ratio (95% CI)
Oddsratio
Odd ratio
Oddsratio (95 % CI)
Odds ratio (95% CI)
Oddsratio (95% CI) 1,68 (1,07; 2,64) p-værdi 0,0246
Odds ratio (95% CI) 1.68 (1.07, 2.64) p-value 0.0246
Oddsratio (OR) (95 % CI)
Odds Ratio (OR) (95%CI)
Oddsratio (versus ipilimumab)
Odds ratio (vs. ipilimumab)
Odefsey bør kun anvendes under graviditet, hvis den potentielle fordel berettiger den potentielle risiko for fosteret.
Odefsey should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Odefsey fås i tabletbeholdere med 30 tabletter samt i pakninger med tabletbeholdere hver med 30 tabletter.
Odefsey comes in bottles of 30 tablets and in packs made up of 3 bottles, each containing 30 tablets.
Odefseys sikkerhed og virkning hos patienter med signifikant, tilgrundliggende leversygdom er ikke klarlagt.
The safety and efficacy of Odefsey in patients with significant underlying liver disorders have not been established.
Odefseys sikkerhed og virkning hos patienter, som samtidig er inficerede med hiv 1 og HBV eller HCV, er ikke klarlagt.
The safety and efficacy of Odefsey in patients co-infected with HIV-1 and HBV or HCV has not been established.
ODIN er et randomiseret, åbent fase III-studie, der sammenligner PREZISTA/ritonavir 800/100 mg en gang dagligt med PREZISTA/ritonavir 600/100 mg to gange dagligt hos ART-erfarne hiv-1-inficerede patienter, hos hvem screening for genotype-resistens har vist, at der ikke fandtes darunavir RAMs (dvs.
ODIN is a Phase III, randomised, open-label trial comparing PREZISTA/ritonavir 800/100 mg once daily versus PREZISTA/ritonavir 600/100 mg twice daily in ART-experienced HIV-1 infected patients with screening genotype resistance testing showing no darunavir RAMs (i.e.
ODIN er et randomiseret, åbent fase III-studie, der sammenligner PREZISTA/ritonavir 800/100 mg en gang dagligt med PREZISTA/ritonavir 600/100 mg to gange dagligt hos ART-erfarne hiv-1-inficerede patienter, hos hvem screening for genotype-resistens har vist, at der ikke fandtes darunavir-RAMs (dvs.
ODIN is a Phase III, randomised, open-label trial comparing PREZISTA/ritonavir 800/100 mg once daily versus PREZISTA/ritonavir 600/100 mg twice daily in ART-experienced HIV-1 infected patients with screening genotype resistance testing showing no darunavir RAMs (i.e.
Odomzo 200 mg hårde kapsler
Odomzo 200 mg hard capsules
Odomzo 200 mg hårde kapsler sonidegib
Odomzo 200 mg hard capsules Sonidegib
Odomzo 200 mg kapsler sonidegib
Odomzo 200 mg capsules Sonidegib
Odomzo er kontraindiceret til fertile kvinder, som ikke overholder Odomzos program for svangerskabsforbyggelse.
Odomzo is contraindicated in women of childbearing potential who do not comply with the Odomzo Pregnancy Prevention Programme.
Odomzo kan give muskelproblemer.
Odomzo may cause muscle problems.
Odomzo skal indtages mindst to timer efter et måltid og mindst en time før det næste måltid.
Odomzo must be taken at least two hours after a meal and at least one hour before the following meal.
Odomzo udgør en teratogen risiko for det ufødte barn, hvis han har ubeskyttet samleje med en gravid kvinde.
Odomzo exposes a teratogenic risk to the unborn child if he engages in unprotected sexual activity with a pregnant woman.
Odomzo udgør en teratogen risiko for det ufødte barn.
Odomzo exposes a teratogenic risk to the unborn child.
Odynofagi
Dry skin
odynofagi, hypermotilitet
odynophagia, hypermotility
Oesophagastomum-orme (voksne stadier)
Oesophagostomum worms (adult stages);
Oesophagitis (alvorlig: 0,4%)
Oesophagitis (severe: 0.4%)
Oesophagostomum spp. (voksne stadier)
Oesophagostomum spp. (adult stages)
Ofatumumab administreres som intravenøs infusion, og absorptionen er derfor ikke relevant.
Ofatumumab is administered by intravenous infusion; therefore, absorption is not applicable.
Ofatumumab elimineres ad to veje: en vej, der er uafhængig af målcellen, som det også er tilfældet med andre IgG-molekyler, samt en målcelle-medieret vej, der er relateret til bindingen til B-celler.
Ofatumumab is eliminated in two ways: a target-independent route like other IgG molecules and a target-mediated route which is related to binding to B cells.
Ofatumumab er udviklet til at binde sig til et protein ved navn CD20, som findes på overfladen af lymfocytter, herunder de maligne lymfocytter, der ses ved kronisk lymfatisk leukæmi.
Ofatumumab has been designed to attach to a protein called CD20 that is found on the surface of lymphocytes, including the cancerous lymphocytes seen in CLL.
Ofatumumab har et lavt fordelingsvolumen med gennemsnitlige Vss-værdier i intervallet fra 1,7 til 8,1 l på tværs af forsøg, dosisniveauer og antallet af infusioner.
Ofatumumab has a small volume of distribution, with mean Vss values ranging from 1.7 to 8.1 l across studies, dose levels, and infusion number.
Ofatumumab har ikke en klinisk relevant indvirkning på chlorambucils eller dens aktive metabolits, phenyleddikesyre kvælstofssennepgas, pharmakokinetik.
Ofatumumab does not have a clinically relevant effect on the pharmacokinetics of chlorambucil or its active metabolite, phenylacetic acid mustard.
Ofatumumab har ikke en klinisk relevant indvirkning på farmakokinetikken af chlorambucil eller dets aktive metabolit, phenyleddikesyre-kvælstofsennepsgas.
Ofatumumab does not have a clinically relevant effect on the pharmacokinetics of chlorambucil or its active metabolite, phenylacetic acid mustard.
Ofatumumab skal være en farveløs til svagt gul opløsning.
Ofatumumab should be a colourless to pale yellow solution.
Ofev 100 mg bløde kapsler er ferskenfarvede, uigennemsigtige, aflange kapsler af blød gelatine med Boehringer Ingelheims logo og tallet “100” præget med sort på den ene side.
Ofev 100 mg capsules are peach-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “100”.
Ofev 100 mg bløde kapsler Ofev 150 mg bløde kapsler
Ofev 100 mg soft capsules Ofev 150 mg soft capsules
Ofev 100 mg bløde kapsler/Ofev 150 mg bløde kapsler fås i følgende pakningsstørrelser:
Ofev 100 mg soft capsules/ Ofev 150 mg soft capsules are available in the following pack-sizes:
Ofev 100 mg kapsler nintedanib
Ofev 100 mg capsules nintedanib
Ofev 150 mg bløde kapsler er brune, uigennemsigtige, aflange kapsler af blød gelatine med Boehringer Ingelheims logo og tallet “150” præget med sort på den ene side.
Ofev 150 mg capsules are brown-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “150”.
Ofev 150 mg kapsler nintedanib
Ofev 150 mg capsules nintedanib
Ofev 150 mg to gange daglig
Ofev 150 mg twice daily
Ofev 150 mg to gangedaglig
Ofev 150 mg twice daily
Ofev er indiceret til behandling af idiopatisk lungefibrose (IPF) hos voksne.
Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Ofev indeholder sojalecithin
Ofev contains soya lecithin
Ofevs sikkerhed og virkning hos børn i alderen 0-18 år er ikke klarlagt.
The safety and efficacy of Ofev in children aged 0-18 years have not been established.
off-label-brug
Off-label use
Officiel batchfrigivelse
Official batch release:
Officiel batchfrigivelse:
Official batch release
Officiel batchfrigivelse: Den officielle batchfrigivelse vil blive foretaget af et statsligt laboratorium eller et laboratorium udpeget hertil i henhold til artikel 114 i Rådets direktiv 2001/83/EØF.
Official batch release: in accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
Officiel batchfrigivelse: i overensstemmelse med artikel 114 i Rådets direktiv 2001/83/EØF vil den officielle batchfrigivelse blive foretaget af et statsligt laboratorium eller et laboratorium beregnet hertil.
Official batch release: in accordance with Article 114 Directive 2001/83/EEC, the official batch release will be undertaken by a state laboratory or a laboratory disignated for that purpose.
Officielle nationale og regionale antibiotikapolitik skal tages i betragtning ved brugen af veterinærlægemidlet.
Official, national and regional antimicrobial policies should be taken into account when the product is used.
Officielle vejledninger vedrørende hensigtsmæssig brug af antibakterielle lægemidler bør tages i betragtning.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Offwhite til lysegul opløselig tablet med ”177” påtrykt den ene flade.
Off-white to light yellow soluble tablet with “177” imprinted on one face.
Oftalmisk (konjunktival og korneal) forkalkning og nefrokalcinose, som manifestationer af hypophosphatasi, er dokumenteret i den publicerede litteratur.
Ophthalmic (conjunctival and corneal) calcification and nephrocalcinosis as manifestations of hypophosphatasia are documented in published literature.
Oftalmiske betablokkere kan fremkalde øjentørhed.
Ophthalmic β-blockers may induce dryness of eyes.
Oftalmologisk undersøgelse (herunder synsskarphedstest, formel synsfelttest og udvidet fundoskopi) blev udført på over 3600 patienter i de kontrollerede kliniske undersøgelser.
Ophthamologic testing (including visual acuity testing, formal visual field testing and dilated funduscopic examination) was conducted in over 3600 patients within controlled clinical trials.
Oftalmologiske betablokkere kan medføre øjentørhed.
Ophthalmic β-blockers may induce dryness of eyes.
Ofte har hypoglykæmi
Have frequent hypos
ofte har hypoglykæmi. har få eller ingen advarselstegn på hypoglykæmi.
have frequent hypos, have few or no warning signs of hypos.
Ofte stillede spørgsmål
Commonly asked questions
Ofte stillede spørgsmål (spørgsmål og svar), patient-sikkerhedskort (skal udleves til patienten): for at give patienter svar på nogle af de spørgsmål, de måtte have vedrørende anvendelse af Xyrem.
Frequently Asked Questions (FAQ) Patient Information Sheet (to be given to the patient): to provide patients with responses to some questions they might have about taking Xyrem.
Ofte stillede spørgsmål Nummervindue
Questions and answers
Ofte stillede spørgsmål og svar
Common Questions and Answers
Oftest indberettet:
Most frequently reported:
Oftest opstå de inden for de første 2-3 dage efter vaccinationen.
They usually happen within 2 to 3 days after vaccination.
og 10
and 1ml of
og 10 flasker med
10 bottles of
og 10 ml uklar lav densitet polyethylen dråbeflasker med polypropylene skruelåg (droptainer).
and 10 ml opaque low density polyethylene bottles with polypropylene screw caps (droptainer).
og 50
and 1ml of
og 95% CI:
70 and 95% CI:
og abstinenssymptomer.
signs of opiate withdrawal.
og alkalisk fosfatase i serum forhøjet, blod- LDH forhøjet, blod- TSH forhøjet, lymfopeni, neutropeni, trombocytopeni
increased, blood LDH increased, blood TSH increased, lymphopenia,
OG BINDEVÆV
AND CONNECTIVE
og bivirkninger af det
effects are recommended when